New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases

Jasmohan S. Bajaj, Giovanni Barbara, Herbert L. DuPont, F. Mearin, Antonio Gasbarrini, Jan Tack

Research output: Contribution to journalReview article

Abstract

Digestive diseases are a broad range of chronic disorders that substantially and negatively impact the patients’ quality of life. Here, we review our current understanding on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease, with a special focus on the gut microbiota composition associated with these disorders. Furthermore, we review the current clinical practice for their therapeutic treatments, including probiotics, diet change, non-adsorbable disaccharides, and antibiotics. We highlight that broad-spectrum non-adsorbable antibiotics, such as rifaximin, are quite effective and safe for the treatment of all essayed digestive diseases.

Original languageEnglish
Pages (from-to)741-749
Number of pages9
JournalDigestive and Liver Disease
Volume50
Issue number8
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

rifaximin
Anti-Bacterial Agents
Hepatic Encephalopathy
Irritable Bowel Syndrome
Disaccharides
Probiotics
Therapeutics
Quality of Life
Diet
Gastrointestinal Microbiome

Keywords

  • Antibiotics
  • Gut microenvironment
  • Therapeutic treatments

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. / Bajaj, Jasmohan S.; Barbara, Giovanni; DuPont, Herbert L.; Mearin, F.; Gasbarrini, Antonio; Tack, Jan.

In: Digestive and Liver Disease, Vol. 50, No. 8, 01.08.2018, p. 741-749.

Research output: Contribution to journalReview article

Bajaj, Jasmohan S. ; Barbara, Giovanni ; DuPont, Herbert L. ; Mearin, F. ; Gasbarrini, Antonio ; Tack, Jan. / New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. In: Digestive and Liver Disease. 2018 ; Vol. 50, No. 8. pp. 741-749.
@article{b23b63b91b70487fb5430ce4ec22aeec,
title = "New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases",
abstract = "Digestive diseases are a broad range of chronic disorders that substantially and negatively impact the patients’ quality of life. Here, we review our current understanding on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease, with a special focus on the gut microbiota composition associated with these disorders. Furthermore, we review the current clinical practice for their therapeutic treatments, including probiotics, diet change, non-adsorbable disaccharides, and antibiotics. We highlight that broad-spectrum non-adsorbable antibiotics, such as rifaximin, are quite effective and safe for the treatment of all essayed digestive diseases.",
keywords = "Antibiotics, Gut microenvironment, Therapeutic treatments",
author = "Bajaj, {Jasmohan S.} and Giovanni Barbara and DuPont, {Herbert L.} and F. Mearin and Antonio Gasbarrini and Jan Tack",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.dld.2018.04.020",
language = "English",
volume = "50",
pages = "741--749",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "8",

}

TY - JOUR

T1 - New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases

AU - Bajaj, Jasmohan S.

AU - Barbara, Giovanni

AU - DuPont, Herbert L.

AU - Mearin, F.

AU - Gasbarrini, Antonio

AU - Tack, Jan

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Digestive diseases are a broad range of chronic disorders that substantially and negatively impact the patients’ quality of life. Here, we review our current understanding on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease, with a special focus on the gut microbiota composition associated with these disorders. Furthermore, we review the current clinical practice for their therapeutic treatments, including probiotics, diet change, non-adsorbable disaccharides, and antibiotics. We highlight that broad-spectrum non-adsorbable antibiotics, such as rifaximin, are quite effective and safe for the treatment of all essayed digestive diseases.

AB - Digestive diseases are a broad range of chronic disorders that substantially and negatively impact the patients’ quality of life. Here, we review our current understanding on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease, with a special focus on the gut microbiota composition associated with these disorders. Furthermore, we review the current clinical practice for their therapeutic treatments, including probiotics, diet change, non-adsorbable disaccharides, and antibiotics. We highlight that broad-spectrum non-adsorbable antibiotics, such as rifaximin, are quite effective and safe for the treatment of all essayed digestive diseases.

KW - Antibiotics

KW - Gut microenvironment

KW - Therapeutic treatments

UR - http://www.scopus.com/inward/record.url?scp=85047405045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047405045&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2018.04.020

DO - 10.1016/j.dld.2018.04.020

M3 - Review article

C2 - 29807873

AN - SCOPUS:85047405045

VL - 50

SP - 741

EP - 749

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 8

ER -